Maraviroc in patients hospitalized for COVID-19

Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19


Description of the Study:

  • Title: Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19.
  • Principal Investigator: Jose Manuel Lomas.
  • Center of Implementation: Hospital Universitario Virgen del Rocio.
  • Study Population: 40 individuals ≥ 18 years of age infected with SARS-CoV-2 and hospitalized or emergency inpatient.
  • Study Type: Phase II national single-center clinical trial.
  • Design: Proof-of-concept trial evaluating standard treatment together with Maraviroc compared to treatment alone.
  • Methods:
    – The experimental group is administered the drug Maraviroc orally daily for 14 days in combination with standard treatment.
    – The standard treatment group is based on the COVID-19 inpatient treatment protocol and will depend on the clinical condition of the patient.

Objectives of the Study:

Principal Objective: To evaluate the safety and efficacy of Maraviroc combined with standard therapy versus standard therapy in relation to clinical progression of COVID-19 in hospitalized patients.

Secondary Objectives:
(1) To analyze changes in analytical variables related to the progression of COVID-19.
(2) To study variation in biomarkers of inflammation.
(3) To analyze changes in innate (monocytes and dendritic cells) and adaptive (T lymphocytes) immune activation.

More about this Study:

Maraviroc is a drug very well tolerated which has been shown to have immune modulating properties, exerting an anti-inflammatory effect in different diseases. In COVID-19 there are very high levels of inflammation that cause damage to organs and systems. This drug could reduce this inflammation leading to a better prognosis of COVID-19.

Positivohuvr

Other Clinical Trials:

CombivacS

Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of…

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

ANTICOV Study: COVID-19 in Africa

Collaborate with ANTICOV study to treat COVID-19 in Africa.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the…

An antiviral mouthwash and COVID-19

Using a mouthwash containing β-cyclodextrin and citrox (bioflavonoids) (CDCM), available in pharmacies, helps reduce the SARS-CoV-2 viral load in saliva.

Pediatric COVID vaccination clinical trial

This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer's COVID vaccine in children under 12 years of age.

LacCOVID Study

The LacCOVID study has shown that milk from lactating women who have been vaccinated with Pfizer-BioNTech contains specific antibodies against the SARS-CoV-2 coronavirus.

Immunomodulatory Treatment In Patients With Severe Pneumonia COVID-19

Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this…

Prevention With Calcifediol Of Respiratory Problems Caused By COVID-19

This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.

Solidarity Trial: COVID-19 Treatments

Solidarity is an international clinical trial to evaluate the effect of a number of drugs for the treatment of COVID-19.